LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company develo...
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Bes...
The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s re...
Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tok...
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Genera...
From advanced biologics and cell therapies to increasingly stringent regulatory expectations, today’s pharmaceutical manufacturing environments dem...
As clinical development grows more complex and globally interconnected, biotech companies are under increasing pressure to build CRO partnerships that deli...
New platform leverages the established Curator® platform methodology to industrialize Lentivirus processes from concept to clinic. Andelyn Bio...
The FDA AMT designation recognizes technologies that demonstrate the potential to significantly improve the quality, reliability, and ...
As biologics, advanced therapies, and specialised injectable medicines continue to reshape the pharmaceutical landscape, the demand for agile and h...
•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operati...
Partnership combines venture creation and biologics discovery to accelerate novel medicines through human clinical proof of concept First-of-its-kind ...
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positiv...
Pierre Fabre Pharmaceuticals, Inc. (PFP), announces it has aligned with FDA on a potential path forward for resubmission of the BLA for tabelecleucel, an...
© 2026 Biopharma Boardroom. All Rights Reserved.
